ChemBriefPolicy Watch: FDA moves toward clinical trials of the psychedelic ibogaine
The US FDA requested public input on designing clinical trials for ibogaine, a psychoactive drug potentially treating opioid addiction and PTSD. Comments are due by Nov. 20 regarding safety, dosing, a
cen · 2026-10-09 00:00